Compugen First Quarter 2015 Conference Call Scheduled for Tuesday, May 5, 2015 at 10:00 AM ET
April 28 2015 - 7:00AM
Business Wire
Compugen Ltd. (NASDAQ: CGEN) today announced that the Company
will host a conference call at 10:00 AM ET on Tuesday, May 5, 2015
to review the first quarter 2015 results. The quarterly results
will be released on the Company’s website (www.cgen.com) prior to
the conference call.
To access the conference call, please dial 1-888-668-9141 from
the US, or +972-3-918-0609 internationally. The call will also
be available via live webcast through Compugen’s website, located
at the following link.
A replay of the conference call will be available approximately
two hours after the completion of the live conference call. To
access the replay, please dial 1-888-295-2634 from the US or
+972-3-925-5925 internationally. The replay will be available
through May 7, 2015.
About Compugen
Compugen is a leading predictive drug discovery company focused
on monoclonal antibodies and therapeutic proteins to address
important unmet needs in the fields of oncology and
immunology. The Company utilizes a broad and continuously
growing integrated infrastructure of proprietary scientific
understandings and predictive platforms, algorithms, machine
learning systems and other computational biology capabilities for
the in silico (by computer) prediction and selection of
novel drug target candidates, which are then advanced in its
Pipeline Program. The discovery and development of monoclonal
antibody therapeutic candidates against selected
Compugen-discovered novel target candidates is performed by
Compugen’s wholly-owned US subsidiary located in South San
Francisco. The Company's business model includes collaborations
covering the further development and commercialization of product
candidates at various stages from its Pipeline Program and various
forms of research and discovery agreements, in both cases providing
Compugen with potential milestone payments and royalties on product
sales or other forms of revenue sharing. For additional
information, please visit Compugen's corporate website at
www.cgen.com.
Forward Looking Statement
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by the use of
terminology such as “will,” “may,” “expects,” “anticipates,”
“believes,” and “intends,” and describe opinions about future
events. These forward-looking statements involve known and unknown
risks and uncertainties that may cause the actual results,
performance or achievements of Compugen to be materially different
from any future results, performance or achievements expressed or
implied by such forward-looking statements. Some of these risks
include: that Compugen’s business model is substantially dependent
on entering into collaboration agreements with third parties and
may not be successful in generating revenues, and that the
development and commercialization of therapeutic products includes
many inherent risks, including failure to receive regulatory
approval. These and other factors are more fully discussed in the
"Risk Factors" section of Compugen’s most recent Annual Report on
Form 20-F as filed with the Securities and Exchange Commission as
well as other documents that may be subsequently filed by Compugen
from time to time with the Securities and Exchange Commission. In
addition, any forward-looking statements represent Compugen’s views
only as of the date of this release and should not be relied upon
as representing its views as of any subsequent date. Compugen does
not assume any obligation to update any forward-looking statements
unless required by law.
Compugen Ltd.Tsipi Haitovsky, +972-52-598-9892Global Media
Liaisontsipih@netvision.net.il
Compugen (NASDAQ:CGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Compugen (NASDAQ:CGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024